110 related articles for article (PubMed ID: 24676028)
1. Decreased serum zinc is an effect of ageing and not Alzheimer's disease.
Rembach A; Hare DJ; Doecke JD; Burnham SC; Volitakis I; Fowler CJ; Cherny RA; McLean C; Grimm R; Martins R; Ames D; Masters CL; Bush AI; Roberts BR
Metallomics; 2014 Jul; 6(7):1216-9. PubMed ID: 24676028
[TBL] [Abstract][Full Text] [Related]
2. Lead and manganese levels in serum and erythrocytes in Alzheimer's disease and mild cognitive impairment: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing.
Hare DJ; Faux NG; Roberts BR; Volitakis I; Martins RN; Bush AI
Metallomics; 2016 Jun; 8(6):628-32. PubMed ID: 26962965
[TBL] [Abstract][Full Text] [Related]
3. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease.
Ellis KA; Bush AI; Darby D; De Fazio D; Foster J; Hudson P; Lautenschlager NT; Lenzo N; Martins RN; Maruff P; Masters C; Milner A; Pike K; Rowe C; Savage G; Szoeke C; Taddei K; Villemagne V; Woodward M; Ames D;
Int Psychogeriatr; 2009 Aug; 21(4):672-87. PubMed ID: 19470201
[TBL] [Abstract][Full Text] [Related]
4. Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).
Ellis KA; Szoeke C; Bush AI; Darby D; Graham PL; Lautenschlager NT; Macaulay SL; Martins RN; Maruff P; Masters CL; McBride SJ; Pike KE; Rainey-Smith SR; Rembach A; Robertson J; Rowe CC; Savage G; Villemagne VL; Woodward M; Wilson W; Zhang P; Ames D;
Int Psychogeriatr; 2014 Apr; 26(4):543-54. PubMed ID: 24252258
[TBL] [Abstract][Full Text] [Related]
5. Selenium Levels in Serum, Red Blood Cells, and Cerebrospinal Fluid of Alzheimer's Disease Patients: A Report from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL).
Cardoso BR; Hare DJ; Bush AI; Li QX; Fowler CJ; Masters CL; Martins RN; Ganio K; Lothian A; Mukherjee S; Kapp EA; Roberts BR;
J Alzheimers Dis; 2017; 57(1):183-193. PubMed ID: 28222503
[TBL] [Abstract][Full Text] [Related]
6. Homocysteine, vitamin B12, and folic acid levels in Alzheimer's disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study.
Faux NG; Ellis KA; Porter L; Fowler CJ; Laws SM; Martins RN; Pertile KK; Rembach A; Rowe CC; Rumble RL; Szoeke C; Taddei K; Taddei T; Trounson BO; Villemagne VL; Ward V; Ames D; Masters CL; Bush AI
J Alzheimers Dis; 2011; 27(4):909-22. PubMed ID: 21891867
[TBL] [Abstract][Full Text] [Related]
7. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease.
Rembach A; Faux NG; Watt AD; Pertile KK; Rumble RL; Trounson BO; Fowler CJ; Roberts BR; Perez KA; Li QX; Laws SM; Taddei K; Rainey-Smith S; Robertson JS; Vandijck M; Vanderstichele H; Barnham KJ; Ellis KA; Szoeke C; Macaulay L; Rowe CC; Villemagne VL; Ames D; Martins RN; Bush AI; Masters CL;
Alzheimers Dement; 2014 Jan; 10(1):53-61. PubMed ID: 23491263
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age.
Buckley R; Saling MM; Ames D; Rowe CC; Lautenschlager NT; Macaulay SL; Martins RN; Masters CL; O'Meara T; Savage G; Szoeke C; Villemagne VL; Ellis KA;
Int Psychogeriatr; 2013 Aug; 25(8):1307-15. PubMed ID: 23693133
[TBL] [Abstract][Full Text] [Related]
9. Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study.
Foster JK; Albrecht MA; Savage G; Lautenschlager NT; Ellis KA; Maruff P; Szoeke C; Taddei K; Martins R; Masters CL; Ames D;
Brain; 2013 Jul; 136(Pt 7):2201-16. PubMed ID: 23737466
[TBL] [Abstract][Full Text] [Related]
10. Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts.
Muenchhoff J; Poljak A; Song F; Raftery M; Brodaty H; Duncan M; McEvoy M; Attia J; Schofield PW; Sachdev PS
J Alzheimers Dis; 2015; 43(4):1355-73. PubMed ID: 25159666
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer's disease.
Oh J; Lee HJ; Song JH; Park SI; Kim H
Exp Gerontol; 2014 Dec; 60():87-91. PubMed ID: 25304332
[TBL] [Abstract][Full Text] [Related]
12. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging.
Gupta VB; Laws SM; Villemagne VL; Ames D; Bush AI; Ellis KA; Lui JK; Masters C; Rowe CC; Szoeke C; Taddei K; Martins RN;
Neurology; 2011 Mar; 76(12):1091-8. PubMed ID: 21422459
[TBL] [Abstract][Full Text] [Related]
13. Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Lim YY; Ellis KA; Harrington K; Ames D; Martins RN; Masters CL; Rowe C; Savage G; Szoeke C; Darby D; Maruff P; The Aibl Research Group
J Clin Exp Neuropsychol; 2012; 34(4):345-58. PubMed ID: 22248010
[TBL] [Abstract][Full Text] [Related]
14. Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: an update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study.
Ellis KA; Rainey-Smith SR; Rembach A; Macaulay SL; Villemagne VL;
Int Rev Psychiatry; 2013 Dec; 25(6):699-710. PubMed ID: 24423223
[TBL] [Abstract][Full Text] [Related]
15. Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease.
Torres LL; Quaglio NB; de Souza GT; Garcia RT; Dati LM; Moreira WL; Loureiro AP; de Souza-Talarico JN; Smid J; Porto CS; Bottino CM; Nitrini R; Barros SB; Camarini R; Marcourakis T
J Alzheimers Dis; 2011; 26(1):59-68. PubMed ID: 21593563
[TBL] [Abstract][Full Text] [Related]
16. Serum thyroid-stimulating hormone as a predictor of cognitive impairment in an elderly cohort.
Forti P; Olivelli V; Rietti E; Maltoni B; Pirazzoli G; Gatti R; Gioia MG; Ravaglia G
Gerontology; 2012; 58(1):41-9. PubMed ID: 21430364
[TBL] [Abstract][Full Text] [Related]
17. Medium-chain plasma acylcarnitines, ketone levels, cognition, and gray matter volumes in healthy elderly, mildly cognitively impaired, or Alzheimer's disease subjects.
Ciavardelli D; Piras F; Consalvo A; Rossi C; Zucchelli M; Di Ilio C; Frazzini V; Caltagirone C; Spalletta G; Sensi SL
Neurobiol Aging; 2016 Jul; 43():1-12. PubMed ID: 27255810
[TBL] [Abstract][Full Text] [Related]
18. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
[TBL] [Abstract][Full Text] [Related]
19. Serum zinc in the progression of Alzheimer's disease.
Dong J; Robertson JD; Markesbery WR; Lovell MA
J Alzheimers Dis; 2008 Nov; 15(3):443-50. PubMed ID: 18997297
[TBL] [Abstract][Full Text] [Related]
20. Bayesian graphical network analyses reveal complex biological interactions specific to Alzheimer's disease.
Rembach A; Stingo FC; Peterson C; Vannucci M; Do KA; Wilson WJ; Macaulay SL; Ryan TM; Martins RN; Ames D; Masters CL; Doecke JD;
J Alzheimers Dis; 2015; 44(3):917-25. PubMed ID: 25613103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
